Paolo Romanelli, MD
Dermatology · Miami, FLNPI 1013945724
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $26,130 of the $39,804 with a category attached, or 65.6%. 22 manufacturers reported payments, led by Boehringer Ingelheim International GmbH at 24.7% of the total. Reporting peaked in 2020 at $13,204 and has fallen 82.6% since, to $2,297 in 2025. Among dermatology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 239 payments — averaging $166.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$10K
- UCB, Inc.$6K
- Novartis$4K
- Sun Pharmaceutical Industries Inc.$3K
- Boehringer Ingelheim$3K
- AbbVie$3K
- plus $10K from 16 others
Across 2 payments — averaging $7014.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$14K
What the payments were for
- Consulting fees$26,13066%
- Speaking & faculty fees$1,8235%
- Travel & lodging$350%
- Food & beverage$11,80830%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 5 | $9,823 |
| UCB, Inc. | 22 | $6,135 |
| Novartis | 55 | $4,258 |
| Sun Pharmaceutical Industries Inc. | 9 | $3,357 |
| Boehringer Ingelheim | 2 | $3,200 |
| AbbVie | 31 | $2,694 |
| Regeneron Healthcare Solutions, Inc. | 23 | $2,281 |
| Dermavant Sciences, Inc. | 4 | $2,259 |
| Johnson & Johnson | 29 | $1,806 |
| EPI Health, LLC | 1 | $1,500 |
| Janssen Scientific Affairs, LLC | 4 | $474 |
| E.r. Squibb & Sons, L.L.C. | 5 | $453 |
| Lilly USA, LLC | 6 | $287 |
| Incyte Corporation | 7 | $278 |
| Galderma Laboratories, L.p. | 6 | $276 |
| Arcutis Biotherapeutics, Inc. | 7 | $190 |
| Amgen | 6 | $158 |
| Sanofi | 2 | $137 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 6 | $125 |
| Pfizer | 3 | $56 |
| Organon | 5 | $37 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$39,804 in reported general payments places this provider in the 90th percentile of 1,147 dermatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 17 | $335,373 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 39 | $277,358 |
| TremfyaGuselkumab | 18 | $239,306 |
| Bimzelx AutoinjectorBimekizumab-Bkzx | 15 | $217,134 |
| Cosentyx (2 Syringes)Secukinumab | 13 | $98,836 |
| Dupixent PenDupilumab | 25 | $93,534 |
| Dupixent SyringeDupilumab | 26 | $91,325 |
| OpzeluraRuxolitinib Phosphate | 28 | $59,419 |
| ZoryveRoflumilast | 12 | $11,336 |
| Tacrolimus | 22 | $2,091 |
| Clobetasol Propionate | 47 | $1,762 |
| Calcipotriene | 12 | $1,688 |
| Triamcinolone Acetonide | 58 | $1,126 |
| Fluocinolone Acetonide | 16 | $790 |
| MethotrexateMethotrexate Sodium | 25 | $462 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $1,806 | $239,30618 claims |
| NovartisCosentyx (2 Syringes) | $4,258 | $98,83613 claims |
| Incyte CorporationOpzelura | $278 | $59,41928 claims |
| Arcutis Biotherapeutics, Inc.Zoryve | $190 | $11,33612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,147 dermatology providers in Florida.
Other dermatology in Miami
- Francisco KerdelMiami$2.1M
- Robert KirsnerMiami$1.4M
- Gil YosipovitchMiami$1M
- Mercedes GonzalezMiami$943K
- Heather Woolery LloydMiami$609K
- Hadar Lev-TovMiami$326K
- Lawrence SchachnerMiami$309K
- Giovanna CioccaMiami$222K
- Janice Lima MaribonaMiami$217K
- Jill WaibelMiami$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.